FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.97
+1.84%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
Market Cap
$827.01M
MomentumView details →
1D Return
+1.84%
YTD Return
+98.29%
RSI (14)
60.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
Market Cap
$827.01M
RSI (14)
60.0
MomentumView details →
1D Return
+1.84%
YTD Return
+98.29%
SummaryUpdated Jun 1, 2026
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage gene therapy company founded in 2013 and headquartered in Emeryville, California. The company went public in December 2020 and focuses on developing innovative gene therapies using proprietary adeno-associated virus (AAV) vectors to treat rare genetic diseases. Since its founding, 4D Molecular has built a pipeline of gene therapy candidates targeting diseases in ophthalmology, cardiology, and pulmonology, with multiple programs currently in clinical trials.
Similar companies
Latest newsMore news →
Bank of America Corp DE increased its stake in 4D Molecular Therapeutics, Inc. by 17.0% during the first quarter, acquiring an additional 141,582 shares, according to a recent SEC filing.11d ago4D Molecular Therapeutics plans to initiate a Phase 3 trial for 4D-150 in diabetic macular edema in Q3 2026.21d ago4D Molecular Therapeutics completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 in wet AMD.67d ago